| Literature DB >> 32997224 |
Aurelia Santoro1, Jiangchao Zhao2, Lu Wu3, Ciriaco Carru4, Elena Biagi5, Claudio Franceschi6.
Abstract
During the course of evolution, bacteria have developed an intimate relationship with humans colonizing specific body sites at the interface with the body exterior and invaginations such as nose, mouth, lung, gut, vagina, genito-urinary tract, and skin and thus constituting an integrated meta-organism. The final result has been a mutual adaptation and functional integration which confers significant advantages to humans and bacteria. The immune system of the host co-evolved with the microbiota to develop complex mechanisms to recognize and destroy invading microbes, while preserving its own bacteria. Composition and diversity of the microbiota change according to development and aging and contribute to humans' health and fitness by modulating the immune system response and inflammaging and vice versa. In the last decades, we experienced an explosion of studies on the role of gut microbiota in aging, age-related diseases, and longevity; however, less reports are present on the role of the microbiota at different body sites. In this review, we describe the key steps of the co-evolution between Homo sapiens and microbiome and how this adaptation can impact on immunosenescence and inflammaging. We briefly summarized the role of gut microbiota in aging and longevity while bringing out the involvement of the other microbiota.Entities:
Keywords: Aging; Evolution; Immunosenescence; Inflammaging; Microbiota
Mesh:
Year: 2020 PMID: 32997224 PMCID: PMC7666274 DOI: 10.1007/s00281-020-00814-z
Source DB: PubMed Journal: Semin Immunopathol ISSN: 1863-2297 Impact factor: 9.623
Fig. 1Co-evolution of Homo sapiens and microbiota. During human evolution, environments underwent drastical modifications, and climate changes, dietary modification, infections, and industrialization have been major selective pressures [26]. Together, host and microbiota evolved an IS able to prevent the colonization of the interior of human body restricting the microbiota at the interface with the body exterior and invaginations, and host IS developed complex mechanisms to identify and destroy invading microbes, while preserving its own bacteria [25]
Predominat bacteria in specific body site
| Predominant phyla | Reference | |
|---|---|---|
| Body site | ||
| Mouth | [ | |
| Nose | [ | |
| Lung | [ | |
| Skin | [ | |
| Gut | [ | |
| Vagina | [ | |
| Genito-urinary tract | [ | |
Summary of the findings on the association of aging with changes in microbiomes from the different body sites
| Body sites | Predominant phyla | Cohort location | Recruited subjects number (age range) | Sequencing stage | Aging-related enrichment taxa | Aging-related decreased taxa | Reference | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Young | Elderly | Longevity | Shannon index | Richness | variation among individuals | ||||||||
| Gut | Sardinia (Italy) | 19 (21–33) | 23 (68–88) | 19 (99–107) | Illumina Hiseq and Miseq | Shotgun metagenomic sequencing and 16S rRNA V3V4 | ≈ | ≈ | ↑ | Methanobrevibacter smithii, Bifidobacterium adolescentis | Faecalibacterium prausnitzii, Eubacterium rectale | [ | |
| Firmicutes, Bacteroidetes | Bologna (Italy) | 20 (25–40) | 43 (59–78) | 21 (99–104) | Phylogentic microarry and qPCR | 16S rRNA | ↓ | ↓ | Anaerotruncus, Oscillospira, Christensenellaceae, Eggerthella | Faecalibacterium, Roseburia, Coprococcus | [ | ||
| Skin | Actinobacteria | Sardinia (Italy) | 19 (21–33) | 23 (68–88) | 19 (99–107) | Illumina Hiseq and Miseq | Shotgun metagenomic sequencing and 16S rRNA V3V4 | Site-dependent alterations | ↑ | Staphylococcus, Streptococcus | Propionibacterium | [ | |
| Actinobacteria | Shangai (China), urban and rural | 24 (25–35) | 22 (50–60) | 454 Pyrosequencing | 16S rRNA | ≈ | ↓ | [ | |||||
| Actinobacteria | Japan | 18 (23–37) | 19 (60–76) | 454 Pyrosequencing | 16S rRNA | ↑ | ↑ | Corynebacterium, Acinetobacter | Propionibacterium, Staphylococcus | [ | |||
| Mouth | Firmicutes (EN), Bacteroidetes (HC) | Osaka, Japan | 16 (79–94) | 15 (68–101) | Pyrosequencing | 16S | Actinomyces, Streptococcus, Bacilli, Selenomonas, Veillonella, Haemophilus (increased in EN) | Prevotella, Leptotrichia, Campylobacter, and Fusobacterium (decreased in EN) | [ | ||||
| Cambridge, USA/São Paulo, Brazil | periodontis: young 152 (28.5 ± 4.7), middle 833 (35–64); periodontally healthy: young 119 (29.24 ± 6.2), middle 112 (35–64) | periodontitis 99 (69.6 ± 4.2); periodontally healthy 15 (67.8 ± 9.8) | Checkerboard DNA–DNA hybridization | Actinomyces (increase d in elderly with periodontal) | P. gingivalis and T. forsythia (increased in younger with periodontal) | [ | |||||||
| Firmicutes | Danbury, CT, USA | 33 (70–82) | 32 (70–82) | illumina Miseq | 16S | ↑(healthy aging) | Streptococcus, Veillonella, and Rothia (NHA) | Neisseria, Haemophilus, Fusobacterium, and Capnocytophaga are enriched in healthy aging. | [ | ||||
| Actinobacteria (in AMD) | Ontario, Canada | 5 (<59–89) | 13 (60>89) | Illumina NextSeq500 | 16S | Propionibacteriales, Rothia, Staphylococcus, and Cornyebacteriaceae (increased in AMD) | Fusobacterium and Bacilli (higher in controls) | [ | |||||
| Nose | Ontario, Canada | 5 (<59–89) | 13 (60>89) | Illumina NextSeq500 | 16S | Actinomycetaceae, Gemella, Proteobacteria, Actinomyces, Veillonella, Burkholderiales (significantly higher in AMD) | Clostridia (increased in the control group) | [ | |||||
| Lung (sputum) | Firmicutes, Proteobacteria, Bacteroidetes, Actinobacteria | Singapore | 24 (22–39) | 24 (60–71) | MiSeq Illumina | 16S | Not significant different | Not significant different | Not significant different | Firmicutes | Proteobacteria (Haemophilus, Lautropia) | [ | |
| Bladder (urine) | Proteobacteria, Firmicutes | Zhejiang, China | 50 (50.06 ± 7.51) | 50 (71.86 ± 6.70) | MiSeq Illumina | 16S V3V4 | ↓ (Not significant) | ↓ (Not significant) | Peptococcus | Lactobacillus, Bifidobacteria | [ | ||
| Firmicutes | UK | 23 (20–29) | 14 (50–59) | Eurofins Genomics | 16S | Not significant different | Not significant different | Mobiluncus | lactobacillus | [ | |||
| Firmicutes, Proteobacteria | Bristol, UK | 13 (20–49) | 20 (50–70+) | 454 Pyrosequencing | 16SV1V3 | Not significant different | Not significant different | Jonquetella, Parvimonas, Proteiniphilum, and Saccharofermentans. | [ | ||||
Vaginal ecosystem is not described in this table because the focus of studies concerning this ecosystem is never the aging per se, but the menopause and associated symptoms, therapies, or conditions
Fig. 2The age-related microbiota changes (dysbiosis) at each body site. Dysbiosis may contribute to inflammaging because long-term stimulation of IS may cause immunosenescence. Such inflammatory state might make the host more sensitive to bacteria, and in turn, alterations in the composition of microbiota are associated with the progression of various pathological conditions in older adults [19]